Different effect of cyclosporine A and mycophenolate mofetil on passive heymann nephritis in the rat

Nephron - Experimental Nephrology

Volumn 100, Issue 2, 2005, Pages

  Blume, Cornelia ^a   Heise, Gunhild ^a   Hess, Alexandra ^a   Waldner, Christoph ^a   Grabensee, Bernd ^a   Schroer, Karsten ^a   Heering, Peter ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

Author keywords

Cyclooxygenase 2; Cyclosporine; Immunosuppressants; Kidney; Mycophenolate mofetil; Passive Heymann nephritis; Prostacyclin; Proteinuria; Thromboxane A2

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 2; CYCLOSPORIN A; FLOSULIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; BODY WEIGHT; CONTROLLED STUDY; DENSITOMETRY; DETERIORATION; FEMALE; HEYMANN NEPHRITIS; KIDNEY FUNCTION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEINURIA; RADIOIMMUNOASSAY; RAT; URINARY EXCRETION; WESTERN BLOTTING;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 2; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; GLOMERULONEPHRITIS; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; RATS; RATS, WISTAR; THROMBOXANE B2;

EID: 20944444129     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085029     Document Type: Article

References (38)

1. Blume C, Heise G, Muehlfeld A, Bach D, Schror K, Gerhardz CD, Grabensee B, Heering P: Effect of flosulide, a selective COX-2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999;56:1770-1778.
2. Wang JL, Cheng HF, Shappell S, Harris RC: A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000;57:2334-2342.
3. Kitahara M, Eitner F, Ostendorf T Kunter U, Janssen U, Westenfeld R: Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 2002;13:1261-1270.
4. Buurman WA, Ruers TJ, Daemen IA, van der Linden CJ, Groenewegen G: MHC class II expression and cyclosporine A. Transplant Proc 1986;18:855.
5. Stahl RAK, Thaiss F, Kahf S, Schoeppe W, Helmchen UM: Immune-mediated mesangial cell injury biosynthesis and function of prostanoids. Kidney Int 1990;38:273-281.
6. Erman A, Chen-Gal B, Rosenfield J: Cyclosporin treatment alters prostanoid and thromboxane production by rat isolated kidney mitochondria. J Pharm Pharmacol 1990;42:181-185.
7. Lee DBN: Nephrology forum. Cyclosporine and the renin-aldosterone axis. Kidney Int 1997;52:248-260.
8. Tomasoni S, Noris M, Zappella S, Gotti E, Casiraghi F, Bonazzola S: Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1989;9:1202-1212.
9. Castrop H, Schweda F, Schumacher K, Wolf A, Kurtz A: Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol 2001;12:867-874.
10. Heise G, Grabensee B, Schroer K, Heering P: Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Nephron 1998;80:220-226.
11. Waldner C, Heise G, Meyer-Kirchrath J, Schroer K, Grabensee B, Heering P: Selective cyclooxygenase-2 inhibition upregulates renal cortical alpha v integrin expression. Nephron Exp Nephrol 2003;93:e72.
12. Meier-Kriesche HU, Steffen BJ, Hochberg AM Gordon RD, Liebman MN, Morris JA: Kaplan mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003;75:1341-1346.
13. Offermann G: Five-year results of renal transplantation on immunosuppressive triple therapy with mycophenolate mofetil. Clin Transplant 2003;17:143-146.
14. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW: Pharmacodynamic assessment of mycophenolic acid induced immunosuppression in renal transplant recipients. Transplantation 1995;62:666-672.
15. Jonsson CA, Carlsten H: Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell Immunol 2002;216:93-101.
16. Shaw LM, Bonner HS, Fields L, Lieberman R: The use of concentration measurements of parent drug and metabolites during clinical trials. Ther Drug Monit 1993;15:483-487.
17. Allison AC, Eugui EM: Purine metabolism and immunosuppressive effects of mycophenolate mofetil. Clin Transplant 1996;10:77-84.
18. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M: Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999;14:58-63.
19. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L: Mycophenolate mofetil vs. cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002;115:705-709.
20. Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G: Use of Mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000;36:250-256.
21. Sekse I, Iversen BM, Daha MR, Ofstad J: Acute effect of passive Heymann nephritis on renal blood flow and glomerular filtration rate in the rat: Role of the anaphylatoxin C5a and the alpha-adrenergic nervous system. Nephron 1992;60:453-459.
22. Iversen BM, Matre R, Tonder O: Indirect haemagglutination for the demonstration of antibodies to renal antigens from rat. Scand J Immunol 1981;99:1199-1210.
23. Salant DJ, Darby C, Couser W: Experimental membranous glomerulonephritis in rats. Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals. J Clin Invest 1982;66:71-81.
24. Feenstra K, van den Lee R, Greben HA, Arends A, Hoedemaker PJ: Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. Lab Invest 1975;32:235-242.
25. Midtvedt K, Fauchald P, Bergan S, Hoieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T: C2 monitoring in maintenance renal transplant recipients: Is it worthwhile? Transplantation 2003;76:1236-1238.
26. Schroer K, Seidel H: Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system. Naunyn Schmiedebergs Arch Pharmacol 1988;337:177-182.
27. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing protein-dye binding. Anal Biochem 1976;72:248-254.
28. Averna M, Barbagallo CM, Ganci A, Giammarresi C, Cefalu AB, Sparacino V, Caputo F, Basili S, Notarbartolo A, Davi G: Determinants of enhanced thromboxane biosynthesis in renal transplantation: Kidney Int 2001;59:1574-1579.
29. Schrijver G, Assmann KJ, Wetzels JF, Berden JH: Cyclosporin A reduces albuminuria in experimental anti-GBM nephropathy independently from changes in GFR. Nephrol Dial Transplant 1995;10:1149-1154.
30. Alavi N, Singh A: Events that stimulate release of thromboxane B2 in passive Heymann nephritis. Proc Soc Exp Biol Med 1997;214:167-172.
31. Remuzzi G, Imberti L, Rossini M, Morelli C, Carminati C, Cattaneo GM, Bertani T: Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. J Clin Invest 1985;75:94-101.
32. Parra T, de Arriba G, Conejo JR, Cantero M, Arribas I, Rodriguez-Puyol D, Rodriguez-Puyol M, Carballo F: Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: Effect of vitamin E on cyclosporine nephrotoxicity. Transplantation 1998;66:1325-1329.
33. Weir MR, Klassen DK, Burdick JF: A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function in cyclosporine treated renal transplant recipients. J Am Soc Nephrol 1992;2:1285-1290.
34. Smith SR, Kubacki VR, Rakhit, A, Martin LL, Schaffer AV, Jasani M, Hefty DJ, Johnston T, Cannon C, Bennett WM, et al: Chronic thromboxane synthase inhibition with CGS 12970 in human CsA nephrotoxicity. Transplantation 1993;56:1422-1426.
35. Schnabel FR, Wait RB, Kahng KU: The relationship of urinary thromboxane excretion to cyclosporine nephrotoxicity. Transplantation 1991;51:686-689.
36. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G: Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 2001;60:653-663.
37. Schloendorff D: Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993;4:643-653.
38. Hoecherl K, Kees F, Kramer BK, Kurtz A: Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. Kidney Int 2004;65:2071-2080.